Frontlight ResearchEarly access
CompletedPhase 4
Herpes zoster after recombinant herpes zoster vaccination - Immediate post-RHZ-vaccination evolution of CMI, HMI and lymphocyte count and typing.
Key facts
- Who runs it
- Centre hospitalier universitaire de Liege
- Where
- Belgium1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 10 people enrolled
- Started
- 1 Jun 2026
- Ended
- 1 Sept 2026
- Type of study
- Interventional
- Record updated
- 16 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Male and female adults between 50 and 65 years of age
- Be healthy
- Willingness to sign the consent form
- Willingness to the 9 blood samples
- Willingness to receive the 2 doses of the RHZ vaccine (at 2-6 months interval)
Who cannot take part
- Intake of any immunosuppressive therapies
- Contraindication for the RHZ vaccine or one or more of the constituents
- Recent live or non-live vaccination(s) (3 months prior to inclusion)
- Prior varicella zoster virus vaccination
- Prior herpes zoster virus vaccination
- History of prior episode of herpes zoster
- Pre-menoposal women
- Any form of immunosuppression
- Unwillingness to sign the consent form
- Active herpes zoster at day 0 of the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate the sequential VZV-specific CMI and HMI as well as the lymphocyte typing before and after recombinant HZ vaccination, to better understand the post-vaccination transient specific VZV immunosuppression.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 16 March 2026